Pure Global AI
NCT06313567Recruiting

Metronomic Capecitabine in Stage III Gastric Cancer

Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial
Fudan UniversityPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
Metronomic capecitabine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Fudan University
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 3
Start date
Mar 10, 2024
End date
Mar 10, 2029
Enrollment
722 participants
Primary outcome

Disease-free survival

Summary

The purpose of this study is to find out whether treatment with metronomic capecitabine will
 improve the survival of gastric cancer patients with stage III who had received standard
 treatment.

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06313567
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06313567 through Pure Global AI's free database. This Phase 3 trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Gastric Cancer. Target enrollment is 722 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.